References
- DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: A balanced overview. Diabetes Care 15: 318-353 (1992) https://doi.org/10.2337/diacare.15.3.318
- Kahn SE, Prigeon RL, McCulloch DK. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42: 1663-1672 (1993) https://doi.org/10.2337/diabetes.42.11.1663
- Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26: 2370-2377 (2003) https://doi.org/10.2337/diacare.26.8.2370
- Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, Gori M, Coppini A, Moghetti P. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism 52: 862-867 (2003) https://doi.org/10.1016/S0026-0495(03)00101-X
- Oudjeriouat N, Moreau Y, Santimone M, Svensson B, Marchis- Mouren G, Desseaux V. On the mechanism of alpha-amylase. Eur. J. Biochem. 270: 3871-3879 (2003) https://doi.org/10.1046/j.1432-1033.2003.03733.x
- Goldstein BJ, Pans M, Rubin CJ. Multi-center, randomized, double-masked, parallel-group assessment of simultaneous glipizide/ metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin. Ther. 25: 890-903 (2003) https://doi.org/10.1016/S0149-2918(03)80112-1
- Hae J. DongEuBoGam. Namsandang, Seoul, Korea (1990)
- Takahashi N, Kawada T, Goto T, Yamamoto T, Taimatsu A, Matsui N, Kimura K, Saito M, Hosokawa M, Miyashita K, Fushiki T. Dual action of isoprenols from herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HepG2 hepatocytes. FEBS Lett. 514: 315-322 (2002) https://doi.org/10.1016/S0014-5793(02)02390-6
- Kamei R, Kadokura M, Kitagawa Y, Hazeki O, Oikawa S. 2'-benzyloxychalcone derivatives stimulate glucose uptake in 3T3-L1 adipocytes. Life Sci. 73: 2091-2099 (2003) https://doi.org/10.1016/S0024-3205(03)00563-0
- Hirai A, Terano T, Hamazaki T, Sajiki J, Saito H, Tahara K, Tamura Y, Kumagai A. Studies on the mechanism of antiaggregatory effect of Moutan Cortex. Thromb. Res. 31: 29-40 (1983) https://doi.org/10.1016/0049-3848(83)90005-1
- Ishida H, Takamatsu M, Tsuji K, Kosuge T. Studies on active substances in herbs used for oketsu ("stagnant blood") in Chinese medicine. V. On the anticoagulative principle in moutan cortex. Chem. Pharm. Bull. (Tokyo) 35: 846-848 (1987) https://doi.org/10.1248/cpb.35.846
- Coniff R, Krol A. Acarbose: a review of US clinical experience. Clin. Ther. 19: 16-26 (1997) https://doi.org/10.1016/S0149-2918(97)80069-0
- Scheen AJ. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diabetes Metab. 24: 311-320 (1998)
- Clissold SP, Edwards C. Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35: 214-243 (1988)
- Hayakawa T, Kondo T, Okumura N, Nagai K, Shibata T, Kitagawa M. Enteroglucagon release in disaccharide malabsorption induced by intestinal alpha2 glucosidase inhibition. Am. J. Gastroenterol. 84: 523-526 (1989)
- Herrmann BL, Schatz H, Pfeiffer A. Continuous blood glucose monitoring: the acute effect of acarbose on blood glucose variations. Med. Klin. 93: 651-655 (1998) https://doi.org/10.1007/BF03044876
- Carrascosa JM, Molero JC, Fermin Y, Martinez C, Andres A, Satrustegui J. Effects of chronic treatment with acarbose on glucose and lipid metabolism in obese diabetic Wistar rats. Diabetes Obes. Metab. 3: 240-248 (2001) https://doi.org/10.1046/j.1463-1326.2001.00102.x